AI Article Synopsis

  • Tuberculosis (TB) is the leading cause of death from infectious diseases globally, and the COVID-19 pandemic worsened TB detection and treatment efforts, reversing progress made prior to 2019.
  • Despite these setbacks, research and development of new TB vaccines continue, aiming for affordable options to be available within the next five years for vulnerable populations.
  • The discussion focuses on the main vaccines being developed against TB, including potential candidates from Brazil that are advancing towards widespread availability.

Article Abstract

Tuberculosis (TB) continues to be the world's leading killer of infectious diseases. Despite global efforts to gradually reduce the number of annual deaths and the incidence of this disease, the coronavirus disease 19 (COVID-19) pandemic caused decreased in TB detection and affected the prompt treatment TB which led to a setback to the 2019 rates. However, the development and testing of new TB vaccines has not stopped and now presents the possibility of implanting in the next five years a new vaccine that is affordable and might be used in the various key vulnerable populations affected by TB. Then, this assay aimed to discuss the main vaccines developed against TB that shortly could be selected and used worldwide, and additionally, evidence the Brazilian potential candidates' vaccines in developing in Brazil that could be considered among those in level advanced to TB end.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452070PMC
http://dx.doi.org/10.1590/0074-02760240093DOI Listing

Publication Analysis

Top Keywords

advances development
4
vaccines
4
development vaccines
4
vaccines tuberculosis
4
tuberculosis brazil's
4
brazil's role
4
role effort
4
effort forward
4
forward strategy
4
strategy tuberculosis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!